Stephen Pflugfelder, MD
Ophthalmology · Houston, TXNPI 1851380216
Payments from drug & device makers
Across 167 payments — averaging $4721.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$216K
- Alcon Research LLC$215K
- Mallinckrodt Hospital Products Inc.$67K
- Dompe US, Inc.$58K
- Kala Pharmaceuticals, Inc.$55K
- F. Hoffmann-la Roche AG$49K
- plus $128K from 19 others
Across 6 payments — averaging $753.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$3K
- KOWA Company, LTD.$2K
- Dompe US, Inc.$232
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 8 | $215,751 |
| Alcon Research LLC | 18 | $214,787 |
| Mallinckrodt Hospital Products Inc. | 4 | $67,460 |
| Dompe US, Inc. | 23 | $58,024 |
| Kala Pharmaceuticals, Inc. | 34 | $55,482 |
| F. Hoffmann-la Roche AG | 6 | $49,025 |
| Regeneron | 19 | $39,389 |
| Shire North American Group Inc | 4 | $24,590 |
| Dompe Farmaceutici S.p.a. | 10 | $13,979 |
| Alcon | 5 | $11,782 |
| Bausch & Lomb Americas Inc. | 5 | $8,120 |
| KOWA Company, LTD. | 2 | $7,500 |
| Novartis | 2 | $7,168 |
| Kowa Research Institute, Inc. | 12 | $7,000 |
| Astrazeneca UK Limited | 1 | $2,100 |
| GSK | 1 | $1,950 |
| Tarsus Pharmaceuticals, Inc. | 4 | $1,647 |
| Aerie Pharmaceuticals, Inc. | 1 | $1,600 |
| Visant Medical, Inc. | 1 | $900 |
| Thea Pharma Inc. | 2 | $82 |
| Sun Pharmaceutical Industries Inc. | 1 | $35 |
| Carl Zeiss Meditec USA, Inc. | 1 | $25 |
| Carl Zeiss Meditec, Inc. | 1 | $16 |
| Sight Sciences, Inc. | 1 | $14 |
| Biotissue Holdings Inc. | 1 | $5 |
How this compares
$788,432 in reported general payments places this provider in the 95th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other ophthalmology in Houston
- David BrownHouston$51.7M
- John MichelettiHouston$3.3M
- Michael CaplanHouston$1.4M
- Shaheen KavoussiHouston$1.3M
- Kevin JongHouston$1.2M
- Stephen SladeHouston$1.2M
- Rosa TangHouston$1.1M
- Zaina Al-MohtasebHouston$1.1M
- Fiaz ZamanHouston$1M
- Christina WengHouston$722K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.